{
    "clinical_study": {
        "@rank": "141346", 
        "acronym": "TAAS", 
        "arm_group": [
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole"
            }, 
            {
                "arm_group_label": "Study Group", 
                "arm_group_type": "Experimental", 
                "description": "Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;"
            }
        ], 
        "brief_summary": {
            "textblock": "Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve\n      Cognitive function in Schizophrenia"
        }, 
        "brief_title": "Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "With atypical antipsychotics for the control group, evaluate cognitive function in\n      schizophrenia patients with antipsychotics combined 5-Hydroxytryptamine 1A (5-HT1A) receptor\n      partial agonist tandospirone"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnostic and Statistical Manual of Mental Disorders-IV Edition (DSM-IV) diagnostic\n             criteria for schizophrenia patients.\n\n          -  18-65 years (including 18 and 65), male or female.\n\n          -  Treated with a stable dose of an AAPD for at least three months.\n\n          -  Informed consent was obtained (if the patient is in the acute phase of schizophrenia,\n             does not have the capacity, their guardians need sign informed consent).\n\n          -  PANSS negative score \u226460.\n\n        Exclusion Criteria:\n\n          -  Combined Axis\u2160mental illness other than schizophrenia;\n\n          -  Taking a mood stabilizer, antidepressants, anticholinergic or anxiolytic drugs, and\n             other drugs improve cognitive function;\n\n          -  Suicidal tendencies;\n\n          -  Have severe or unstable heart, liver, kidney, endocrine, blood and other medical\n             disease patients\n\n          -  Clinically significant ECG or laboratory abnormalities were\n\n          -  Glaucoma and epilepsy;\n\n          -  Unsupervised or unable to take prescribed medication;\n\n          -  History of alcohol and drug abuse;\n\n          -  Allergic;\n\n          -  Pregnant or lactating woman;\n\n          -  Patients participate in other clinical trials during a month;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040883", 
            "org_study_id": "DSPC-SED20130516"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Control Group", 
                    "Study Group"
                ], 
                "description": "Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.", 
                "intervention_name": "Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole", 
                "intervention_type": "Drug", 
                "other_name": "AAPD"
            }, 
            {
                "arm_group_label": "Study Group", 
                "description": "Tandospirone\uff0c30mg per day", 
                "intervention_name": "Tandospirone", 
                "intervention_type": "Drug", 
                "other_name": "Sediel"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antipsychotic Agents", 
                "Risperidone", 
                "Quetiapine", 
                "Olanzapine", 
                "Aripiprazole", 
                "Ziprasidone", 
                "Tandospirone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Schizophrenia", 
            "Tandospirone", 
            "Cognitive Therapy"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "contact": {
                "email": "qingyun2000@hotmail.com", 
                "last_name": "qingyun Yin"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510170"
                }, 
                "name": "Guangzhou Psychiatric Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia", 
        "overall_contact": {
            "email": "qingyun2000@hotmail.com", 
            "last_name": "Qingyun Yin"
        }, 
        "overall_official": {
            "affiliation": "Guangzhou Psychiatric Hospital", 
            "last_name": "Qingyun Yin", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measurement and treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery(MCCB) total score", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 12 weeks of  treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040883"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangzhou Psychiatric Hospital", 
            "investigator_full_name": "Qingyun Yin", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "MATRICS Consensus Cognitive Battery(MCCB) factor score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 weeks of treatment"
            }, 
            {
                "measure": "Positive and Negative Syndrome Scale(PANSS) total score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 weeks of treatment"
            }, 
            {
                "measure": "Positive and Negative Syndrome Scale(PANSS) factor score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 weeks of treatment"
            }, 
            {
                "measure": "Personal and Social Performance Scale(PSP) total score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 weeks of treatment"
            }, 
            {
                "measure": "Clinical Global Impression(CGI) factor score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 weeks of treatment"
            }, 
            {
                "measure": "Treatment Emergent Symptom Scale(TESS) factor score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 weeks of treatment"
            }, 
            {
                "measure": "Functional magnetic resonance imaging(FMRI)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 weeks of treatment"
            }
        ], 
        "source": "Guangzhou Psychiatric Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qingyun Yin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}